Navigation Links
PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
Date:1/10/2011

BOSTON, Jan. 10, 2011 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL) will release Second Quarter Fiscal Year 2011 financial results on Monday, January 31, 2011 after the close of the stock market.  The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PR Newswire website at www.prnewswire.com.

PAREXEL will host a conference call and live webcast at 10:00 a.m. EST on Tuesday, February 1, 2011 to discuss the results.  To access the webcast, visit PAREXEL's website at www.PAREXEL.com, and click on the Investors menu.  This webcast will continue to be accessible for one year following the live broadcast.  To participate via telephone, dial (706) 758-4950 and ask to join PAREXEL's Second Quarter Fiscal Year 2011 conference call.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:James Winschel, Senior Vice-President and Chief Financial OfficerJill Baker, Corporate Vice President, Investor Relations+1-781-434-4118Email: Jill.Baker@PAREXEL.com
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
2. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
3. PAREXEL Issues Updated Financial And Operational Information
4. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
5. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
6. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
7. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
8. PAREXEL International to Present at the Wachovia Equity Conference
9. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
10. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
11. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):